A functional genetic screen for metabolic proteins unveils GART and the de novo purine biosynthetic pathway as novel targets for the treatment of luminal A ERα expressing primary and metastatic invasive ductal carcinoma
Targeting tumor cell metabolism is a new frontier in cancer management. Thus, metabolic pathway inhibitors could be used as anti-estrogen receptor α (ERα) breast cancer (BC) drugs. Here, the interplay among metabolic enzyme(s), the ERα levels and cell proliferation was studied. siRNA-based screen di...
Main Authors: | Manuela Cipolletti, Stefano Leone, Stefania Bartoloni, Filippo Acconcia |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-04-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2023.1129162/full |
Similar Items
-
Possible Therapeutic Strategy Involving the Purine Synthesis Pathway Regulated by ITK in Tongue Squamous Cell Carcinoma
by: Kaoru Onidani, et al.
Published: (2021-07-01) -
Purine metabolism in plant pathogenic fungi
by: Manli Sun, et al.
Published: (2024-02-01) -
Ouabain and Digoxin Activate the Proteasome and the Degradation of the ERα in Cells Modeling Primary and Metastatic Breast Cancer
by: Claudia Busonero, et al.
Published: (2020-12-01) -
A New Anti-Estrogen Discovery Platform Identifies FDA-Approved Imidazole Anti-Fungal Drugs as Bioactive Compounds against ERα Expressing Breast Cancer Cells
by: Manuela Cipolletti, et al.
Published: (2021-03-01) -
Studies of the purine biosynthetic pathways in the gastrointestinal tract.
by: LeLeiko, Neal Simon
Published: (2014)